Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRRX3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $40,184
Award facts
- Contract value 100% obligated
- $40,183.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 26, 2026, for $40,183.95 in firm fixed-price pharmaceutical supply, under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).
The order calls for XOLAIR 300 MG/2 ML syringes. Place of performance is Park Ridge, Illinois. Ultimate completion date is April 16, 2026. DMS Pharmaceutical Group Inc. is a woman-owned small business. The order was issued without set-aside designation.
Quick answers
Who was awarded contract SPE2DR26FRRX3?
SPE2DR26FRRX3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on March 26, 2026.
How much is contract SPE2DR26FRRX3 worth?
The government has obligated $40,184 on SPE2DR26FRRX3.
Is contract SPE2DR26FRRX3 an order under another contract?
Yes. SPE2DR26FRRX3 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRX3 competed?
The extent of competition for SPE2DR26FRRX3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award